Tests early cholesterol lowering with recaticimab in people with acute ischemic stroke
Tests recaticimab, a cholesterol-lowering drug, given before clot removal in stroke patients.
Plain-language title generated from the registry record
Registry title: Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
Where in China
- Shanghai East Hospital, Tongji UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai East Hospital
- Trial code
- NCT07002476
- Record updated
- 2 September 2026
- Original description
EAST-LDL is a prospective, multicenter, randomized, open-label clinical trial with blinded endpoint assessment evaluating whether early intensive lipid lowering with the PCSK9 inhibitor recaticimab, administered before endovascular therapy, improves functional outcome in patients with acute ischemic stroke due to anterior-circulation large-vessel occlusion. Participants are randomized to recaticimab plus guideline-recommended standard of care or standard of care alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0-2 at 90 ± 7 days.Read full original descriptionShow less
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
EAST-LDL is a prospective, multicenter, randomized, open-label clinical trial with blinded endpoint assessment evaluating whether early intensive lipid lowering with the PCSK9 inhibitor recaticimab, administered before endovascular therapy, improves functional outcome in patients with acute ischemic stroke due to anterior-circulation large-vessel occlusion. Participants are randomized to recaticimab plus guideline-recommended standard of care or standard of care alone. The primary outcome is favorable functional outcome, defined as a modified Rankin Scale score of 0-2 at 90 ± 7 days.
Inclusion: Adults (age 18 years and older); Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2); Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines; Provision of informed consent by the patient or his/her legally authorized representative (or by an appropriate agent according to local requirements).
Exclusion: Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment; Severe, concomitant non-cardiovascular disease expected to reduce life expectancy to less than 3 months; Pre-existing functional impairment, with mRS score >2; Patients who are allergic to PCSK9 inhibitors; Other conditions deemed unsuitable for inclusion in the clinical study by the investigator; Severe renal insufficiency, defined as estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73m2 at final screening; Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal; ASPECTS score ≤5 on cranial CT imaging; Pregnant or lactating women; Patients who are participating in other clinical trials.